FDA Approves ZEVALIN(R) Expanded Label as Part of First-Line Therapy…
Published by Food and Drug Administration News September 6th, 2009 in UncategorizedSpectrum Pharmaceuticals , a commercial-stage biotechnology company with a focus in oncology, today announced ZEVALIN , a CD20-directed radiotherapeutic antibody, received approval from the U.S. Food and Drug Administration for an expanded label for the treatment of patients with previously untreated follicular non-Hodgkin’s Lymphoma , who achieve …